About NEXT FUNDS TOPIX 17 Pharmaceutical ETF

1621 invests in stocks. The fund's major sectors are Health Technology, with 97.03% stocks, and Consumer Non-Durables, with 1.53% of the basket. The assets are mostly located in the Asia region.

1621 top holdings are Daiichi Sankyo Company, Limited and Takeda Pharmaceutical Co. Ltd., occupying 22.35% and 22.30% of the portfolio correspondingly.

1621 last dividends amounted to 535.00 JPY. The year before, the issuer paid 646.00 JPY in dividends, which shows a 20.75% decrease.

1621 assets under management is ‪4.96 B‬ JPY. It's fallen 12.50% over the last month.

1621 fund flows account for ‪2.51 B‬ JPY (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.

1621 shares are issued by Nomura Holdings, Inc. under the brand NEXT FUNDS. The ETF was launched on Mar 21, 2008, and its management style is Passive.

1621 expense ratio is 0.32% meaning you'd have to pay 0.32% of your investment to help manage the fund.

1621 follows the No Underlying Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.

1621 invests in stocks.

1621 price has risen by 0.26% over the last month, and its yearly performance shows a −8.29% decrease. See more dynamics on 1621 price chart.
NAV returns, another gauge of an ETF dynamics, showed a 8.74% increase in three-month performance and has decreased by −5.76% in a year.